Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Nazha

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Leukemia & Lymphoma|June 22, 2017
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)Srinivasa R Sanikommu, Michael J Clemente, Peter Chomczynski, et al.
Leukemia|October 19, 2019
Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndromeJibran Durrani, Hassan Awada, Ashwin Kishtagari, et al.
Blood Cancer Journal|December 15, 2017
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careAziz Nazha, Mikkael A Sekeres, Rami Komrokji, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Cancer Cell|September 29, 2015
hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic MalignanciesMiguel Gallardo, Hun Ju Lee, Xiaorui Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Blood Advances|July 20, 2019
Distinct clinical and biological implications of <i>CUX1</i> in myeloid neoplasmsMai Aly, Zubaidah M Ramdzan, Yasunobu Nagata, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Leukemia & Lymphoma|June 22, 2017
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)Srinivasa R Sanikommu, Michael J Clemente, Peter Chomczynski, et al.
Leukemia|October 19, 2019
Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndromeJibran Durrani, Hassan Awada, Ashwin Kishtagari, et al.
Blood Cancer Journal|December 15, 2017
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careAziz Nazha, Mikkael A Sekeres, Rami Komrokji, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Cancer Cell|September 29, 2015
hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic MalignanciesMiguel Gallardo, Hun Ju Lee, Xiaorui Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Blood Advances|July 20, 2019
Distinct clinical and biological implications of <i>CUX1</i> in myeloid neoplasmsMai Aly, Zubaidah M Ramdzan, Yasunobu Nagata, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Pageof 13